Lyndsey A. Reich

TL;DR: These findings suggest that cancer vaccine given prior to local tumor irradiation augments an immune response targeted at tumor antigens that results in specific anti-tumor immunity and support further exploration of the combination of radiotherapy with cancer vaccines for the treatment of cancer.

TL;DR: Treatment with LG 268, a RXR agonist, can improve response to immune checkpoint blockade in HER2+ or triple-negative breast cancer, and data suggest that the use of LG268, the only rexinoid approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma, can be improved.

TL;DR: The results validate the screening paradigm for in vitro testing of novel rexinoids and demonstrate the potential for MSU-42011 to be developed for the treatment of KRAS-driven lung cancer.

TL;DR: The essential roles that RXR and partner receptors play in T cells, dendritic cells, macrophages and epithelial cells, especially within the tumor microenvironment are described, and the promise of combining rexinoids with approved checkpoint blockade therapies in order to enhance efficacy of the latter and to delay or potentially eliminate drug resistance is supported.

TL;DR: In this paper , a series of novel rexinoids and selected V-125 as the lead based on performance in optimized in vitro assays were evaluated in clinically relevant mouse models of breast and lung cancer.